Ceretas raises A$8M in IPO to fund brain-device trials
What's the deal? University of Queensland spin-out CeretasDealroom has a profile for this one. Try Dealroom → has raised A$8 million in an initial public offering, valuing the medical technology firm at A$18 million. It sold 32 million shares at 25¢ each and could begin trading on the local bourse as early as next week.
What's the endgame? Ceretas develops portable ultrasound devices designed to treat brain conditions such as Alzheimer's disease. The IPO proceeds are earmarked to fund clinical trials.
Why now? The company fast-tracked the listing after the offering fetched strong demand.
The signal: The debut shows investor appetite for early-stage medical technology tied to neurological disease — a large and largely unmet market — even at a modest valuation.
Read more: Australian Financial Review
Image credit: National Institutes of Health (NIH)
